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 The human-associated microbiota has been the focus of much current research, with 
the microbiota inhabiting the gastrointestinal tract of particular interest. These organisms play 
many roles in human health and well-being. However, shifts in the composition of the 
intestinal microbiota have been associated with diseases such as irritable bowel syndrome, 
inflammatory bowel disease, and colon cancer. Several recent studies have reported on the 
distal gut microbiota composition of healthy adults and those with IBS, while there is a lack 
of studies devoted to adolescents. This study utilized a custom-designed Affymetrix 
Microbiota Array capable of detecting 775 phylo-species of intestinal bacteria to determine 
the composition of the distal gut microbiota of 22 adolescents suffering from IBS-D 
(diarrhea-predominant) and 22 healthy adolescents. High sample-to-sample variation was 
observed in both groups at genus level. While some differences were observed in mean 
relative abundance of several bacterial genera between IBS-D and healthy adolescents, 
including Bifidobacterium, Lactobacillus, Veillonella, and Prevotella, these differences were 
not significant. Sample groups also failed to separate in PCA space. Therefore, we cannot 
conclude that the distal gut microbiota of adolescents with IBS-D is significantly different 
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Introduction to the Human Intestinal Microbiota 
Unique microbial communities are found in many different niches on Earth, 
including communities within the soil, fresh and saltwater, on the leaves of plants, and those 
associated with animals. Both vertebrates and invertebrates harbor prokaryotes which play 
important roles in health and disease. Birds and mammals have high numbers of prokaryotes 
associated with the skin, and especially the gastrointestinal tract (Whitman, et al., 1998). 
Virtually every surface on the human body that is exposed to the outside environment is 
colonized by microbes, including, but not limited to, the skin, oral cavity, respiratory tract, 
esophagus, and genitourinary tract (Sekirov, et al., 2010). According to Willett et al., there 
are approximately 103-104 bacterial cells/cm2 on the human skin, except in the groin and 
axilla where the density increases approximately 1000-fold to 106 cells/cm2. This pales in 
comparison to the vast numbers that are found throughout the gastrointestinal tract, which 
contains up to 100 trillion bacterial cells, with the vast majority located within the colon.  
All three domains of life, bacteria, eukarya, and archaea, can be found within the 
human intestinal tract (Whitman et al., 1998). According to Ley et al., 2006, within a given 
intestinal habitat, some of the microbial members function as “residents,” which would 
generally be always present in fairly stable numbers within the intestinal tract, while others 
act more like “hitchhikers”, resulting from ingested food, water, and the environment, and 
may not always be present within the gastrointestinal tract of an individual. While the 
bacterial population density in the gastrointestinal environment is among the highest known, 
the diversity of the major phyla present is actually quite limited as compared to the diversity 
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found in other environments, such as the soil and ocean. The human gastrointestinal 
microbiota is composed of mainly obligate anaerobes, dominated by the phylum Firmicutes, 
followed by Bacteroidetes and Actinobacteria. Several other phyla can also be found in the 
gastrointestinal tract, although they are much less abundant. They include Proteobacteria, 
Spirochaetes, Fusobacteria, Verrucomicrobiae, and Lentisphaerae. Frank et al. examined 
biopsy samples from the small intestine and colon of healthy individuals, and noted that the 
small intestine samples were composed mainly of Bacilli, Streptococcaceae, Actinobacteria, 
Actinomycinaceae, and Corynebacteriaceae, while colon samples were dominated by 
Bacteroidetes and Lachnospiraceae. A few acid-tolerant bacterial genera were detected in the 
stomach; they included Lactobacillus, Veillonella, and Helicobacter. 
The colon is estimated to contain approximately 70% of all microbes associated with 
the human body (Sekirov et al., 2010). According to Gebbers et al., 1989, the surface area of 
the human gut is similar to that of a tennis court (200m2), which provides a very large area for 
microbial colonization. The number of microbes in the human gastrointestinal tract increases 
dramatically moving from the stomach, to the small intestine, and into the colon. Starting at 
the stomach, there are approximately 10 bacterial cells per gram of contents, increasing to 103 
cells/gram in the duodenum, 104 cells/gram in the jejunum, 107 cells/gram in the ileum, and 
1012 cells/gram in the colon (Sekirov et al., 2010). Collectively, these microorganisms contain 
100 times more genes than the human genome (Sartor et al., 2008). Moving from the stomach 
to the colon, oxygen levels and pH change drastically, therefore; the composition and 
diversity of the inhabiting microbes vary greatly between the different areas of the 
gastrointestinal tract. The stomach has a pH of about 2, while the proximal small bowel 
ranges from 5.5-7.0, and the distal ileum from 6.5-7.5. In the caecum, a decrease in pH is 




 The human intestinal microbiota plays many roles in human health and well-being. 
Among those roles are carbohydrate and fiber degradation, modulation of uptake and 
deposition of dietary lipids, production of certain vitamins and short-chain fatty acids, 
development and proper stimulation of the immune system, modulation of gut motility, and 
protection of the host from intestinal pathogens (Sekirov et al., 2010).  Germ-free animals 
were observed to require higher caloric intake to maintain the same body weight as control 
animals. A study by Backhed, et al., 2005, looked at germ-free versus conventionally-raised 
mice. They noted that the conventionally-raised mice had 40% more body fat than the germ-
free mice, even though the germ-free mice ingested more food. They also experimented with 
transplantation of the gastrointestinal microbiota from conventionally-raised mice into germ-
free mice. This resulted in the body fat levels of the germ-free mice becoming similar to that 
of conventionally-raised mice. These studies prompted more research into the mechanisms 
that are employed by the intestinal microbiota to maximize the nutrient availability of 
ingested food (Sekirov et al., 2010). Since the conventionally-raised mice were ingesting 
fewer calories, yet still gained more weight than the germ-free mice, it is reasonable to infer 
that the gastrointestinal microbiota may be degrading certain nutrients into compounds that 
can be absorbed and utilized by the host. Many non-digestible carbohydrates including 
polysaccharides, oligosaccharides, fiber, and lignin are optimal energy sources for the colonic 
microbiota. (Jacobs, et al., 2009) These compounds are broken down into monosaccharides 
and short chain fatty acids (SCFA). The major SCFA’s produced as a result of bacterial 
fermentation, which mainly takes place in the proximal colon, include acetate, propionate, 
and butyrate. Butyrate, in addition to being the major energy source for colonocytes, has been 
examined for its effects on human health. Some studies indicate that butyrate may protect 
against colon cancer (Hu, et al., 2011, Tang, et al., 2011), intestinal inflammation, and 
oxidative stress (Hamer, et al., 2008). Levels of different SCFA’s can be measured in fecal 
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extracts through the use of NMR or gas chromatography (Jacobs, et al., 2009, Murphy et al., 
2010). 
Certain bacterial phyla present in the colon are responsible for breaking down 
carbohydrates into specific SCFAs. The Firmicutes, which are important starch and fiber 
degraders, make up the majority of bacteria present in the colon, and include genera such as 
Ruminococcus, Faecalibacterium, Roseburia, Papillibacter, and Clostridium. The main 
carbohydrate fermentation products of the Firmicutes include acetate, lactate, formate, 
butyrate, and succinate (Jacobs, et al., 2009). Bacteroidetes, which include major genera such 
as Bacteroides and Prevotella, are responsible for production of acetate, propionate, and 
succinate. Actinobacteria, represented in the colon mainly by Bifidobacterium, produce 
lactate, acetate, and formate. 
 
Initial colonization of the human intestinal tract 
 Prior to birth, the intestinal tract of the human fetus is sterile. While the intestinal 
tract is first colonized within hours after birth,  the mode of delivery and feeding is important 
in determining the types of bacteria that will first colonize the intestinal tract. It is thought 
that the early intestinal microbial community could affect future fiber fermentation, short 
chain fatty acid metabolism, and vitamin K synthesis (Biasucci). This initial colonization is 
also thought to be important in the development of the immune system. Vaginally-delivered 
infants are colonized with microorganisms from the mother’s intestinal and vaginal 
microbiota, while those delivered by Cesarean section are colonized with microorganisms 
from the skin and environment (Biasucci, et al., 2010). Penders, et al., 2006, report that 
Cesarean-delivered infants had lower numbers of Bifidobacterium and Bacteroides and were 
more likely to be colonized with Clostridium difficile than vaginally-delivered infants. They 
also found that infants who were delivered vaginally at home and were breastfed exclusively 
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seemed to harbor the highest numbers of “beneficial” microbes. These infants had the highest 
numbers of Bifidobacterium and lowest numbers of E. coli and C. difficile, while formula-fed 
infants were more often colonized with E. coli, C. difficile, Bacteroides, and Lactobacillus. 
During the first year of life, the composition of the microbial residents of the 
gastrointestinal tract is much simpler and less diverse than that of an older child or adult, and 
varies widely between individual infants. Both infants and adults are exposed to microbes by 
ingesting milk and other foods, however, infants are much more likely to actually be 
colonized by these organisms rather than healthy adults with established gastrointestinal 
microbial communities (Mackie, et al., 1999). After the first year of life, the intestinal 
microbiota becomes more stable and starts to resemble that of children and young adults 
(Mackie, et al., 1999). There is also a shift from facultative anaerobes, mainly Enterobacteria, 
to strict anaerobes (Hopkins, et al., 2005). As facultative anaerobes colonize the colon, they 
consume oxygen, which enables obligate anaerobes, such as Clostridia, Bifidobacteria, and 
Bacteroides, to enumerate (Enck et al., 2009). Obligate anaerobic species dominate the colon 
in children and adults. Enck et al., 2009 studied fecal samples by conventional culture 
techniques from over 12,000 infants and children up to 18 years of age. They found that 
Bacteroides spp. and lactobacilli increased with age, while Enterococci and E. coli decreased, 
and Bifidobacteria numbers remained stable.  
 
Microbiota in Human Disease 
 While our intestinal microbiota plays several important roles in human health, as 
discussed previously, many recent studies have suggested that deviations in certain types of 
bacteria may be linked to several diseases, such as irritable bowel syndrome (IBS) (Matto, et 
al., 2005, Maukonen, et al., 2006, Kassinen, et al., 2007, Krogius-Kurrika, et al., 2009, Tana, 
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et al., 2010), inflammatory bowel disease (IBD) (Friswell et al., 2010), and possibly even 
colon cancer (Sobhani et al., 2011).  
 
Irritable Bowel Syndrome  
 According to Longstreth et al., 2006, IBS is a common disorder worldwide, with 
approximately 10-20% of adults and adolescents affected. It is a functional bowel disorder 
that has varied symptoms among those affected, but is associated generally with abdominal 
pain, bloating, and changes in bowel habit, but without any visible damage or high-level 
inflammation to the large intestine as seen in patients suffering from Crohn’s disease and 
ulcerative colitis. Although IBS does not cause as severe of an illness as IBD, it still 
significantly affects the quality of life (Salonen, et al., 2010). The Rome III criteria are used 
to group IBS-affected individuals into three groups based on stool form and frequency: IBS-
D (diarrhea-predominant), IBS-C (constipation-predominant), and IBS-M (mixed, or 
alternating) (Salonen, et al., 2010, Longstreth, et al., 2006). For a diagnosis of IBS to be 
made, pain must be experienced at least 3 days per month over 3 consecutive months, and the 
pain must have two of the following three features: (Karantanos, et al., 2010) 
1. Relief after defecation 
2. Onset of pain associated with change in stool frequency 
3. Onset of pain associated with change in stool form 
Unfortunately, the actual pathophysiology of IBS is very complex and not yet completely 
understood. While deviations in the intestinal microbiota have been noted in studies involving 
healthy subjects vs. IBS-affected subjects, other factors are also thought to be involved, such 
as visceral hypersensitivity, abnormal gut motility, autonomous nervous system dysfunction, 
and psychological factors, such as stress and anxiety (Karantanos, et al., 2010). Low-level 
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inflammation of the GI mucosa in IBS patients has also been reported in several studies 
(Aerssens, et al., 2008, Chadwick, et al., 2002, Macsharry, et al., 2008). 
 
Irritable Bowel Syndrome and the Intestinal Microbiota 
 According to Salonen, et al., 2010, there are three main convincing pieces of 
evidence that tie the intestinal microbiota to involvement in IBS. The first involves the 
correlation between gastrointestinal infections and a particular type of IBS, post-infectious 
irritable bowel syndrome (PI-IBS). The gastrointestinal microbiota has also been shown to be 
altered in IBS patients in many recently published studies involving subjects with different 
subtypes of IBS. In addition, other studies have shown that IBS symptoms can be improved 
with treatments that are meant to alter the composition of the intestinal microbiota, such as 
probiotics, prebiotics, and antibiotics.  
 
Post-infectious IBS 
After a gastrointestinal infection, some patients (7-31%) will go on to develop what 
is known as PI-IBS. Most studies of PI-IBS have involved adult patients. While IBS affects 
approximately 14% of high school patients and 6% of middle school patients, a study by 
Marshall, et al., 2006, reported a high incidence of post-infectious IBS symptoms (36%) in 
88 children with positive stool culture results. Microorganisms that are most often associated 
with PI-IBS include Salmonella spp., Campylobacter jejuni, and Shigella spp. The length and 
severity of the infection are also important factors in the likelihood of developing PI-IBS. 
According to Neal, et al., 1997, an illness that lasts longer than 3 weeks has a relative risk of 
11.4 compared to an illness lasting less than 1 week. Antibiotic use also increases the risk of 
PI-IBS. Maxwell, et al., 2002, state that patients who were given antibiotics were 4 times 




SIBO (Small Intestinal Bacterial Overgrowth) and IBS 
 Small intestinal bacterial overgrowth, or SIBO, is a condition that is characterized by 
abnormally high numbers of bacteria (>105 organisms/ml) present in the proximal small 
intestine, which leads to a competition for nutrients between the host and the bacteria (Rana, 
et al., 2008, Scarpellini, et al., 2009). As a result of unusually high bacterial catabolism in 
this area of the intestine, toxic metabolites are produced, which can cause injury to the 
intestinal enterocytes (Rana, et al., 2008). Symptoms include chronic diarrhea, flatulence, 
nausea, and abdominal pain (Rana, et al., 2008). The proper method for SIBO diagnosis has 
been debated, but it is generally diagnosed by aspiration and culture of the jejunal contents, or 
with lactulose breath testing (Posserud, et al., 2007, Scarpellini, et al., 2009). In a study by 
Bouhnik, et al., 1999, jejunal samples from patients with suspected SIBO were cultured, and 
bacterial genera recovered included microaerophiles Streptococcus, E. coli, Staphylococcus, 
Micrococcus, Klebsiella, and Proteus, and anaerobes Lactobacillus, Bacteroides, 
Clostridium, Veillonella, Fusobacterium, and Peptostreptococcus.  
 SIBO has been shown to be associated with IBS. In a 2009 study by Scarpellini, et 
al., 2009, children with IBS and healthy children were given lactulose breath tests (LBT), and 
they found that the LBTs were abnormal in 65% of children with IBS, while only 7% were 
abnormal in control children. Several adult studies also suggest a correlation between SIBO 
and IBS (Lupascu, et al., 2005, Pimentel, et al., 2003, Carrara, et al., 2008, Majewski, et al., 
2007, Posserud, et al., 2007). Treatment of SIBO usually involves antibiotics. Broad-
spectrum antibiotics have been effective against Gram negative organisms. Other antibiotics, 
such as norfloxacin, amoxicillin, rifaximin, chlortetracycline, and ciprofloxacin were also 
used in treatment of SIBO (Rana, et al., 2008). Posserud treated seven SIBO patients with 
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ciprofloxacin, and five showed decreased levels of small-intestinal bacteria after treatment. 
Three patients reported an improvement of symptoms after treatment.  
 
Recent Studies of Intestinal Microbiota Among Different IBS Subtypes 
 While there have been a number of recent studies (Lyra, et al., 2009, Matto, et al., 
2005, Maukonen, et al., 2006, Kassinen, et al., 2007, Krogius-Kurrika, et al., 2009, Tana, et 
al., 2010) aimed to determine whether there are significant differences in the intestinal 
microbiota between healthy subjects and IBS subjects, the results of these studies do not 
show a particular consensus, which may be due to the varying experimental methods used. 
Among these methods are conventional culturing, DGGE, qPCR, sequencing, FISH, and 
microarray technology, or a combination of these methods. In addition, methods such as 
qPCR only allow for study of specifically selected groups of bacteria. The majority use the 
Rome II criteria for recruitment of subjects, and all involve adult subjects. 
 
Stability and Variability of IBS Microbiota vs. Healthy Microbiota 
 A culturing and DGGE-based study by Matto, et al., 2005, suggested that IBS 
subjects showed greater temporal instability (changes over time) of their intestinal microbiota 
than healthy controls. However, some of the IBS subjects were on antibiotics, which may 
explain this finding. A slightly higher number of coliforms and a higher proportion of aerobes 
to anaerobes were also reported. A follow-up study by Maukonen, et al., 2006, also studied 
temporal stability of the microbiota of IBS vs. healthy subjects by DGGE, and also looked at 
the abundance of certain groups of bacteria by affinity capture, a type of quantitative 
hybridization-based technique. Similar to the findings by Matto, greater temporal instability 
of IBS microbiota as compared to healthy controls was reported. They also saw a decrease in 
the proportion of the C. coccoides-E. rectale group in IBS-C subjects compared to healthy 
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controls. In contrast to the previous two studies, a DGGE-based study by Codling, et al., 
2010, reported greater instability and variation in healthy subjects compared to IBS subjects.  
 
Key Differences Observed in the Microbiota of IBS Subtypes 
 Kassinen, et al., 2007, reported a significantly altered fecal microbiota in IBS. After 
16S rRNA library sequencing, they noted decreases in Collinsella aerofaciens, Clostridium 
cocleatum, and Coprococcus eutactus in IBS subjects, which were verified by qPCR.  
Another 16S rRNA library sequencing and qPCR-based study by Krogius-Kurrika, et al., 
2009, found significant differences between IBS-D subjects and healthy controls. They saw 
increases in Proteobacteria and Firmicutes in IBS-D subjects, with a particular increase in the 
family Lachnospiraceae within Firmicutes. Decreased Actinobacteria and Bacteroidetes were 
also observed compared to healthy controls. A qPCR-based study by Lyra, et al., 2009, 
measured levels of 14 different bacterial phylotypes in IBS-D, C, M, and healthy controls. 
After multivariate analysis, they reported that the microbiota of IBS-D subjects differed the 
most from all other sample groups. Increased Ruminococcus torques and Clostridium 
thermosuccinogenes in IBS-D subjects, and increased Ruminococcus bromii in IBS-C 
subjects were observed compared to controls. C. thermosuccinogenes was also found to be 
increased in IBS-M subjects, while R. torques was decreased as compared to healthy controls. 
A second qPCR-based study by Malinen, et al., 2005, examined levels of 20 bacterial 
phylotypes. Decreased Lactobacilli were seen in IBS-D subjects compared to IBS-C. An 
increase in Veillonella was observed for IBS-C subjects compared to healthy controls. 
Overall, in IBS subjects Bifidobacterium catenulatum was decreased, while Ruminococcus 
productus and C. coccoides were increased compared to healthy controls. Tana, et al., 2010, 
reported higher levels of Veillonella and Lactobacillus in IBS patients compared to controls. 
This study also examined levels of SCFA’s, and found that IBS patients had higher levels of 
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acetic, propionic, and total organic acids, which are known to be produced by a combination 
of Lactobacillus and Veillonella. Higher levels of acetic and propionic acids also correlated 
positively with increasingly worse GI symptoms associated with IBS.  
 
Treatment of IBS 
 While there is no known cure for IBS at this time, treatments are available that can 
help manage symptoms of IBS. The main goal of IBS treatment is to improve symptoms 
(abdominal pain, bloating, constipation, diarrhea); thereby improving the quality of life for 
the patient. As mentioned previously, SIBO has been treated with antibiotics. Although low-
level inflammation has been reported in the GI mucosa of IBS patients, (Aerssens, et al., 
2008, Chadwick, et al., 2002, Macsharry, et al., 2008) treatment with anti-inflammatory 
drugs such as prednisolone have not been very effective in improvement of IBS symptoms 
(Dunlop, et al., 2003). Other drugs, such as smooth muscle relaxants, tricyclic 
antidepressants, SSRI’s, and anticonvulsants have been used in treatment of abdominal pain 
associated with IBS with some success (Lacy, et al., 2009). 
 Other treatment options that have been widely used and studied are probiotics and 
prebiotics. Probiotics are live bacteria which are administered to the host, usually through a 
food product (yogurt, for example) or as a capsule. Generally, they include one or more 
members of the genera Bifidobacterium, Lactobacillus, or Streptococcus. Microorganisms 
given as probiotics are considered to be beneficial in some way to the host. Once in the host, 
some of the bacteria must survive the acidic environment of the stomach and eventually 
establish in the colon among the existing colonic microbiota. In order for this to happen, the 
bacteria must be administered in large doses over a period of time. Possible health benefits of 
probiotics include competitive interactions with pathogenic bacteria, production of 
compounds that inhibit the growth of other bacteria, modulation of intestinal inflammatory 
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response, and enhancement of the mucosal barrier function (Quigley, et al., 2010). Prebiotics, 
on the other hand, are nondigestible compounds, typically galacto- or fructo-oligosaccharides 
that selectively stimulate the growth of certain beneficial bacteria, such as Lactobacillus and 
Bifidobacterium (Quigley, et al., 2010). 
 
How do we study the intestinal microbiota? 
 In order to understand how changes in the composition of the intestinal microbiota 
relate to certain disease states (irritable bowel syndrome, inflammatory bowel disease) the 
basic composition of the normal, “healthy” microbiota must be determined. The vast majority 
of studies use fecal samples or intestinal biopsies as a means of sampling the intestinal 
microbiota. Of those studies, fecal samples seem to be used most frequently, mainly due to 
the ease and non-invasive nature of collection. In some cases though, fecal samples may not 
be ideal. Biopsy specimens may need to be collected for studies focused on the microbiota 
associated specifically with the colonic mucosa or the small intestine.  
The “classic” method of studying intestinal microbiota involved culturing bacteria 
from fecal or biopsy samples onto differential media to select for certain groups, and then 
counting the resulting colonies. Culturing was very time-consuming and labor intensive, and 
identification of bacteria to the species or strain level was impossible. The majority of gut 
microbiota are strict anaerobes, which also makes sample preservation and culturing difficult. 
In addition, an estimated 80% of the gut microbiota cannot be cultured due to their unknown 
nutritional requirements (Eckburg, et al., 2005). Later, molecular-based methods were put 
into practice. Instead of culturing live bacteria from fecal samples, these methods generally 
involve extracting DNA or RNA from the bacteria and then amplifying a portion or all of the 
16S ribosomal RNA gene for study. This gene is very useful for determining the composition 
of complex microbial communities because it has been highly conserved through evolution. 
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The beginning and end of the gene are highly conserved; therefore, universal bacterial 
primers can be designed for these regions and the entire 16S rRNA gene can be amplified by 
PCR. Primers can also be designed to variable regions of the gene in order to amplify 16S 
rRNA sequences for only a certain desired subset of bacteria. Some of the common methods 
used recently in studies of intestinal microbiota composition will be briefly discussed in the 
following sections. 
 
Molecular Methods Used to Study Intestinal Microbiota 
Full-length 16S rRNA sequencing (Sanger sequencing) was used in a study by 
Eckburg, et al., 2005, to determine the diversity and composition of the colonic microbiota 
from three healthy individuals. Basically, the “pool” of 16S rRNA sequences were compared 
and then divided into operational taxonomic units (OTU’s) based on their percent sequence 
identity, or similarity. As the number of samples to be analyzed increases, full-length 
sequencing can be very costly (Sekirov, et al., 2010). Pyrosequencing is used to amplify 
select variable regions of the 16S rRNA gene, and can have 100-fold higher throughput than 
Sanger sequencing (Sekirov, et al., 2010). The most significant advantage of sequencing 
methods is the ability to detect completely new phylo-species of bacteria. Other methods that 
can be used to study the composition of the intestinal microbiota include DGGE (denaturing 
gradient gel electrophoresis), TRFLP (terminal restriction fragment length polymorphisms), 
FISH (fluorescent in-situ hybridization), and qPCR. For the most part, these methods have 
the advantage of being less costly than DNA sequencing, but they cannot give nearly as 
“complete” a picture of the intestinal microbiota as a whole as DNA sequencing can.  DNA 
fingerprinting methods such as DGGE and TRFLP, for example, are based on the ability of 
different DNA fragments to be resolved on a gel. However, if a particular phylotype is 
present at a low abundance, it is unlikely to be detected by these methods. FISH can be very 
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useful under certain circumstances, and low cost is a definite advantage. This method uses 
16S rRNA-targeted oligonucleotide probes that are labeled with some type of fluorescent 
molecule. These probes can be targeted to large groups of bacteria (phylum or class) or much 
more specific groups. Generally though, only a small number of different probes are used 
simultaneously for these experiments. qPCR, like FISH, can either be targeted to broad or 
very specific groups of bacteria. It is often used as a confirmatory method to FISH 
experiments, or vise versa (Sekirov, et al., 2010).  
 
Microarray technology: a new way of studying intestinal microbiota 
A more recently introduced, high-throughput method for studying the intestinal 
microbiota is the DNA microarray. In a general sense, microarrays contain nucleic acid 
probes that are complementary to nucleic acid sequences present in the community of 
interest. These probes are affixed at one end to a glass slide or some other surface in a 
particular order. Microarray technology in the present day has been applied to many areas of 
biological research, such as gene expression in cancer cells, gene upregulation and 
downregulation in bacterial and eukaryotic cells under particular conditions, and microbial 
community composition studies, to name a few examples. Microarrays used for studying 
microbial communities are mainly 16S rDNA based. Early applications of 16S rDNA 
microarrays in microbial community analysis were much smaller in scale, containing probes 
towards a limited number of specific bacterial species, probes for higher phylogenetic groups 
of bacteria, or both (Wang, et al., 2004).  
In recent years, several custom 16S rDNA-based microarrays have been developed to 
study complex microbial communities, including the HITChip (Human Intestinal Tract Chip), 
PhyloChip, and the Microbiota Array that was recently developed in the Paliy laboratory. 
(Paliy, et al., 2009, Brodie, et al., 2006, Rajilic-Stovanovic, et al., 2009) The probes on these 
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arrays were developed based on bacterial 16S rDNA sequence information, and contained 
much higher numbers of probes that aimed to interrogate much larger and more diverse 
bacterial populations. The PhyloChip, which was the earliest of these efforts, contains 
approximately 500,000 unique probes to bacterial species (Brodie, et al., 2006). The 
HITChip, developed by Rajilic-Stovanovic, et al., contains probes to 1140 distinct bacterial 
phylo-species, and was validated by interrogating bacterial 16S rDNA from fecal samples 
from young adults and elderly adults, and comparing to results obtained by FISH. The 
authors also noted the better reproducibility and reliability of results of the microarray 
compared to results obtained by DGGE. Paliy, et al., 2009 also recently developed a custom 
Microbiota Array designed to interrogate the intestinal microbiota, which contains probes to 
775 unique bacterial phylo-species. Validation experiments correctly identified genomic 
DNA from 15 different bacterial species. The sensitivity of the microarray was also tested; 30 
cycles of 16S PCR dropped the detection limit from 4ng to 10pg of genomic DNA. The 
Microbiota Array was also recently employed to demonstrate how the number of PCR cycles 
affects bacterial detection and also to examine differences between bacterial presence and 
metabolic activity (Rigsbee, et al., 2011). This study also proposed mathematical algorithms 
to account for cross-hybridization of 16S rDNA and for the varying numbers of 16S gene 
copies in different bacterial groups. After these adjustments were taken into account, results 
were more consistent with FISH data (Rigottier-Gois, et al., 2003, Lay, et al., 2005), 
suggesting that certain groups of bacteria were previously over-represented and others under-
represented. While these microarrays were all designed to study intestinal microbiota, the 





 The work described in this thesis involves a quantitative comparison of the 
composition of the intestinal microbiota between healthy adolescents (n=22) and adolescents 
diagnosed with irritable bowel syndrome (n=22) through the use of a custom Microbiota 
Array, as described and validated by Paliy, et al., 2009. While there have been previous 
studies of the intestinal microbiota of adult IBS patients, this study is the first to our 
knowledge to present a comprehensive, high-throughput view of the composition of the distal 
gut microbiota of healthy and IBS adolescents. In addition, Agans, et al., 2011, recently 
showed that the distal gut microbiota of adults is different than that of adolescents. Bacterial 
gDNA was isolated from fecal samples. 16S rDNA was amplified by PCR, fragmented, and 
loaded onto the microarray. Microarrays were processed in duplicate for each fecal sample. 
Microarray results were analyzed as described in Materials and Methods. Microarray data 





2. MATERIALS AND METHODS 
 
Fecal Sample Collection and Preservation 
 Fresh fecal samples were collected into sterile containers by healthy adolescent 
volunteers (n=22) and newly-diagnosed IBS-D (IBS, diarrhea-predominant) adolescent 
volunteers (n=22) as approved by the Wright State IRB committee. For healthy samples, the 
age of the donors ranged from 9 to 18 years with a median of 12. For IBS-D samples, the age 
of the donors ranged from 8 to 18 years with a median of 13.5. For both sample groups, 10 
donors were male and 12 were female. Samples were delivered to Children’s Medical Center, 
Dayton, Ohio, and frozen at -80˚C.  
 
Bacterial Genomic DNA Isolation 
 After homogenization of the fecal samples, bacterial genomic DNA was isolated 
from each fecal sample with the ZR Fecal DNA Mini Kit (Zymo Research) by Mr. 
Harshavardhan Kenche at Children’s Medical Center. Specifically: 
 
a. 150 mg of homogenized fecal sample and 750 µl of Lysis Solution were added to a 
Bashing Bead tube. 
b. Tubes were processed in Disruptor Genie for 5 minutes. 
c. Tubes were centrifuged at 10,000 g in microcentrifuge for 1 minute. 
d. 400 µl of supernatant was transferred to Zymo-Spin IV Spin Filter in a collection 
tube and centrifuged for 1 minute at 7000 g. 
18 
 
e. 1200 µl of Fecal DNA Binding Buffer was added to filtrate and mixed well. 
f. 800 µl of mixture from Step 5 was added to Zymo-Spin IIC Column in a collection 
tube and centrifuged for 1 minute at 10000 g.  
g. Flow through was discarded, and previous step was repeated. 
h. 200 µl of DNA Pre-Wash Buffer was added to Zymo-Spin IIC Column in a new 
collection tube and centrifuged for 1 minute at 10000 g.  
i. 500 µl of DNA Wash Buffer was added to the Zymo-Spin IIC Column in a collection 
tube and centrifuged for 1 minute at 10000 g.  
j. The Zymo-Spin IIC Column was transferred to 1.5ml Eppendorf tube. 100ul of 
DNase/RNase free water was added to column matrix. Column was centrifuged for 
30 seconds at 10000 g. 
k. Eluted DNA was transferred to prepared Zymo-Spin HRC-IV spin column and 
centrifuged for 1 minute at 8000 g. This column is meant to remove PCR inhibitors 
that are typically present in fecal samples.  
 
The concentration of isolated genomic DNA was measured on the Nanodrop 1000 
spectrophotometer and an aliquot of each sample was also run on an agarose gel to check 
quality. If quality was not sufficient, samples were reisolated.  
 
Amplification and Purification of 16S rDNA 
 PCR amplification of 16S rDNA was carried out for fecal genomic DNA samples 
using universal 16S-rDNA specific bacterial primers Bact_27F_v4 
(5’AGRGTTYGATYMTGGCTCAG-3’) and Univ_1492R 
(5’GGYTACCTTGTTACGACTT-3’), with 250ng of starting gDNA in each reaction. 25 




Table 2.1: PCR Reaction Mix 
 
Component Amount 
Genomic DNA 250 ng 
Bact_27F_v4 1 µl 
Univ_1492R 1 µl 
Nuclease-free Water Up to 50 µl
Taq 2X Master Mix 25 µl 
 
Table 2.2: Thermocycler Protocol 
 
Step 1 95C for 2:00 
Step 2 (Repeat x25) 95C for 0:30 
Step 3 (Repeat x25) 55C for 0:30 
Step 4 (Repeat x25) 72C for 1:30 
Step 5 72C for 10:00
 
 The four PCR reactions for a particular sample were pooled after amplification for 
purification with the Qiagen Qiaquick PCR Purification Kit. Specifically: 
a. Five volumes of Buffer PB were added to one volume of the PCR reaction, 
transferred to a PCR purification column and centrifuged at 17,900 g for 1 minute.   
b. The flow-through was discarded and 750 µL of Buffer PE were added to the column, 
and column was centrifuged for 1 minute at 17,900 g.   
c. Flow-through was discarded, and the column spun down again to ensure removal of 
buffer. 
d. The spin column was transferred to a new collection tube and 30 µL of RNase free 
water, heated to 50˚C, was added to the center of the column and let to sit for 2 
minutes  




The concentration of the purified 16S rDNA was measured on the Nanodrop 
spectrophotometer and an aliquot of each sample was also run on an agarose gel to check for 
the expected 1.5kbp band.  
 
Fragmentation of 16S rDNA with DNase I 
  Ideally, 16S rDNA should be in fragments of 100-300bp for hybridization to the 
microarray. 1800ng of 16S rDNA was subjected to fragmentation with DNase I (NEB) at a 
concentration of 0.04U/µg.  
  
 
Table 2.3: Fragmentation Reaction 
 
Component Amount 
16S rDNA 1800 ng 
DNase I (0.04 U/µl) 1.8 µl 
10x DNase Buffer 4 µl 
Nuclease-free Water Up to 40 µl
Total Volume 40 µl 
 
Figure 2.1: Polyacrylamide gel showing proper fragmentation  
 
Figure 2.1 shows an ethidium-bromide stained polyacrylamide gel showing an example of 





 Components were mixed well in a 0.5ml Eppendorf tube and placed in the 
thermocycler, incubated at 37˚C for 10 minutes, followed by 98˚C for 10 minutes to 
inactivate the enzyme. 300ng of fragmented 16S rDNA were combined with water and gel 
loading dye and loaded onto a 10% polyacrylamide gel along with a 100-bp DNA ladder to 
check for proper fragmentation.  
 
 
Terminal Labeling with Biotin 
 The remaining 1500ng of 16S rDNA fragments were end-labeled with biotin. The 
reaction was mixed well and incubated at 37˚C for 1 hour in the thermocycler. Reactions 
were stopped with the addition of 2µl of 0.5M EDTA. 
 
Table 2.4: Labeling Reaction 
 
Component Amount
Fragmented 16S rDNA 1500 ng 
CoCl2 5 µl 
Terminal Transferase (Tdt) 2 µl 
10x Tdt Buffer 5 µl 
GeneChip Labeling Reagent 2 µl 
Nuclease-free Water 2.7 µl 
Total Volume 50 µl 
 
 
Hybridization to Microarray 
 
 Hybridization mixtures were prepared and loaded directly into the Microbiota Array. 




Table 2.5: Hybridization Mixture 
Component Amount
Fragmented, labeled 16S rDNA 1500 ng 
2X Hybridization Buffer 65 µl 
Control Oligo B2 2.2 µl 
100% DMSO 10.2 µl 
10 mg/ml Herring Sperm DNA 1.3 µl 
50 mg/ml BSA 1.3 µl 
Total Volume 130 µl 
 
Washing, Staining, and Scanning of Affymetrix Microarrays 
 After 16 hours of hybridization, microarrays were removed from the oven. The 
hybridization mix was removed from the microarray, frozen at -20˚C and replaced with 160 
µl of Wash Buffer A.  Staining solutions were prepared according to the Affymetrix protocol. 
Washing and staining of the microarrays was carried out on the Affymetrix GeneChip 
Fluidics Station 450, using the “Midi_euk_2v3_450” protocol. Scanning of the microarrays 
was carried out on the Affymetrix GeneChip Scanner.  
 
 
Table 2.6: Staining solutions prepared for microarray washing and staining  
Streptavidin Vial 1 Amount
2x Stain Buffer 300 µL 
50 mg/ml BSA 24 µL 
1 mg/ml Streptavidin 6 µL 
H2O 270 µL 
Total Volume 600 µL 
   
Antibody Soln. Vial 2 Amount
2x MES Stain Buffer 300 µL 
50 mg/ml BSA 24 µL 
10 mg/ml Goat IgG 6 µL 
0.5 mg/ml Anti-strep 6 µL 
H2O 270 µL 
Total Volume 600 µL 
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SAPE Soln. Vial 3 Amount
2x MES Stain Buffer 300 µL 
50 mg/ml BSA 24 µL 
1 mg/ml SAPE 6 µL 
H2O 270 µL 
Total Volume 600 µL 
 
Quantitative Real-Time PCR Analysis (qPCR) 
 Two gDNA samples (one from each sample group) were chosen for qPCR analysis 
based on their contrasting microarray results for relative abundance of selected genera. A 
standard curve was constructed by combining equal amounts of genomic DNA from each 
sample chosen for qPCR analysis. Reactions with five gDNA starting amounts (50pg, 200pg, 
1ng, 4ng, 10ng) were run in duplicate for each primer pair. The 27F_v4 primer was used as 
the forward primer for all reactions, and reverse primers were either selected from literature 
or developed using Ribosomal Database Project (http://rdp.cme.msu.edu/). All qPCR 
reactions were carried out on the Abi Prism 7000 (Applied Biosystems) using Perfecta SYBR 
Green Supermix (Quanta Biosciences). One genomic DNA sample from each sample group 
was chosen based on the contrasting relative abundance values of the genera selected for 
qPCR analysis (at least a two-fold difference in relative abundance was desired). Reactions 
were run in triplicate with genomic DNA starting amounts of 500ng and 4ng for each primer 
pair.  
Table 2.7: Reverse primers used for qPCR analysis 
Reverse Primer Sequence (5’→3’) Source 
Eub_338R_3W (universal) GCWGCCWCCCGTAGGWGT Amann et al., 1990 
Bifi_162R (Bifidobacterium) CCGGYATTACCACCCGTTT Agans et al., (in press) 
Osci_236R (Papillibacter) TCAGACGCGAGGCCATCTTTC Agans et al., (in press) 
Prev_496R (Prevotella) CGGAATTAGCCGGTCCTTAT Matsuda et al., 2009 






 Data were initially processed in Affymetrix Gene Chip Operating System (GCOS), 
which provides raw signal values and presence/absence calls for probesets. Normalization of 
data was carried out with CARMAweb (Rainer) (https://carmaweb.genome.tugraz.at/carma/) 
using the MAS5 algorithm for background correction, VSN for normalization, MAS5 for PM 
correction, and Median Polish for expression. After normalization, data were inserted into a 
custom Microsoft Excel template developed by Dr. Paliy which calculates bacterial 
abundances at different phylogenetic levels. It also corrects for cross-hybridization and for 
the varying numbers of 16S gene copies in different bacterial genera. 16S copy numbers were 
obtained from rrnDB (http://ribosome.mmg.msu.edu/rrndb/index.php) and NCBI Genome 
Project (http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi). If the average 16S copy number 
for a particular bacterial genus could not be found, higher phylogenetic levels were examined.  
 Heatmaps were produced with Genesis (http://genome.tugraz.at/) to show the 
variation in relative abundance at class and genus levels among individual samples. Principal 
Components Analysis of experiments was also performed by importing log2-adjusted signal 
values into Genesis. Moderated t-tests with BH adjustment were run using CARMAweb to 
determine if there were significant differences at class and genus level between sample 
groups.  
 Core microbiota was assessed by determining the numbers of phylo-species present 
in all samples for both groups and for each individual sample. The numbers of shared phylo-
species (present in at least two samples) and unique phylo-species (present in only one 
sample) were also calculated.  
qPCR data was analyzed using a custom Microsoft Excel template. For standard 
curves, the log of the DNA starting amount was plotted against Ct values for each primer pair 
and a slope was calculated. From the slope values, efficiency values were calculated to allow 
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for unequal amplification rates for different primer pairs. For individual qPCR experiments, 
average Ct values for each primer pair were assessed against the standard curve using the 
Excel template. Relative abundance values of each genus being assessed were calculated with 
the template. Ratios of each genus between tested samples were also calculated and compared 








Fecal samples were collected from twenty-two healthy adolescents and twenty-two 
adolescents suffering from IBS-D. Bacterial gDNA was extracted from each fecal sample and 
16S rDNA was amplified via PCR using universal primers as described. 16S rDNA was 
fragmented, end labeled with biotin, and hybridized to the Microbiota Array. Microarrays 
were washed, stained, and scanned according to Affymetrix protocol. Duplicate microarrays 
were processed for each fecal sample with amplified 16S rDNA from separately run PCR 
reactions. After analyzing the microarray results in Affymetrix GCOS, raw signal values 
were normalized in CARMAweb for both kHLT (healthy adolescent) and kIBS (IBS 
adolescent) fecal samples. Normalized signal values and presence/absence calls for all 
probesets were copied into the custom Microsoft Excel template to examine the abundance of 
bacterial groups at different phylogenetic levels.  
 
Correlation of Replicate Microarrays 
 Pearson correlations of signal values for duplicate microarrays were automatically 
calculated by the custom Microsoft Excel template. On average, the Pearson correlation for 





Comparison of Intestinal Microbiota Abundance at the Class Level 
At class level, both kHLT and kIBS groups were dominated by Clostridia, at 72.1% 
and 73.5% mean relative abundance, respectively, followed by Actinobacteria, Bacteroidetes, 
and Bacilli (Table 3.1).  Generally, as mean abundance decreased for a particular class, the 
coefficient of variation increased. Clostridia, the most abundant class, had the lowest 
variation from one sample to the next. However, the least abundant classes, such as 
Alphaproteobacteria, Spirochaetes, and Verrucomicrobiae had much higher variation across 
samples. In many cases, these low-abundance classes were not present in every fecal sample. 
Pearson correlations of signal values for replicate microarrays were also determined for low-
abundance classes only (Alpha, Beta, Gamma, and Deltaproteobacteria, Mollicutes, 
Verrucomicrobiae, and Lentisphaerae). For kHLT samples, the average Pearson correlation 
for low abundance classes was 0.79±0.08, and 0.86±0.07 for kIBS samples. Since these 
values were lower than those calculated for all classes, it may indicate that the high variation 
in abundance values for low abundance classes could be due in part to differences in probeset 
signal values between replicate microarrays. No significant differences in abundance were 
found at class level between kHLT and kIBS samples (p<0.05).  
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Alphaproteobacteria 0.1% 0.1% 414.7% 0.0% 0.0% - 
Betaproteobacteria 0.7% 0.1% 92.6% 0.7% 0.1% 91.1% 
Gammaproteobacteria 0.5% 0.1% 121.9% 0.7% 0.2% 98.7% 
Deltaproteobacteria 0.9% 0.2% 80.3% 0.6% 0.1% 94.0% 
Epsilonproteobacteria 0.0% 0.0% - 0.0% 0.0% - 
Clostridia 72.1% 1.1% 7.1% 73.5% 1.4% 9.0% 
Mollicutes 1.3% 0.3% 107.1% 1.2% 0.2% 79.9% 
Bacilli 4.3% 0.4% 45.3% 4.8% 0.4% 37.0% 
Actinobacteria 10.2% 0.9% 43.8% 8.7% 1.1% 61.9% 
Spirochaetes 0.1% 0.0% 218.6% 0.0% 0.0% 154.6% 
Bacteroidetes 8.5% 0.6% 31.5% 8.7% 0.7% 39.7% 
Fusobacteria 0.0% 0.0% - 0.0% 0.0% - 
Verrucomicrobiae 1.2% 0.2% 92.2% 0.8% 0.2% 127.3% 
Lentisphaerae 0.2% 0.2% 421.1% 0.1% 0.1% 460.5% 
Table 3.1 presents mean abundance, standard deviation, and variation at class level for kHLT 
and kIBS samples.  
 
  
Figure 3.1 presents heatmaps showing the variation in relative abundance of the four 
most abundant bacterial classes among individual kHLT and kIBS fecal samples. The upper 
maximum (shown in red) was set to 80% relative abundance, and the minimum was set to 
zero. This was done to ensure that the variations in relative abundance values for all classes 
could be visualized in the heatmap. Class Clostridia ranged from 63.5% to 83.4% relative 
abundance in kHLT samples and from 58.9% to 85.1% in kIBS samples, while relative 
abundance of Bacteroidetes ranged from 0.0% to 13.2% in kHLT samples, and 2.6% to 
16.4% in kIBS samples. Actinobacteria also showed wide variation among individual 
samples, with relative abundance of 0.2% to 21.1% in kHLT samples and 0.1% to 17.5% in 
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kIBS samples. Actinobacteria are mainly represented in the colon by the genus 
Bifidobacterium, which is frequently included in probiotic supplements and yogurts. 
Consumption of Bifidobacterium-containing products may help to explain the high variability 
of Actinobacteria levels between samples. Bacilli, the fourth most abundant class, ranged 
from 1.0% to 7.7% in kHLT samples, and 2.1% to 10.4% in kIBS samples.  
 








Figure 3.1A shows the variation in relative abundance at class level for kHLT samples and 




Comparison of Intestinal Microbiota Detection at Class Level 
 The average number of probesets detected for each class was also assessed for kHLT 
and kIBS samples, which refers to the number of bacterial phylo-species called present by the 
Microbiota Array. The array contains probesets for 775 different bacterial phylo-species, and 
the mean total number of probesets detected was equal for both sample groups at 306, which 
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corresponds to 39% of all probesets being called present for both sample groups. Bacterial 
detection varied widely among individual samples in both groups. For kHLT samples, the 
number of present probesets ranged from a minimum of 207 (27%) to a maximum of 406 
(52%), while kIBS samples showed similar results with a minimum of 215 (28%) to a 
maximum of 399 (51%).  
 












































































Alphaproteobacteria 0.3 0.1 203.1% 0.3 0.1 167.1% 
Betaproteobacteria 2.0 0.2 55.6% 2.7 0.3 48.0% 
Gammaproteobacteria 2.9 0.3 44.9% 4.4 0.3 34.3% 
Deltaproteobacteria 1.2 0.2 81.1% 0.7 0.2 105.5% 
Epsilonproteobacteria 0.1 0.1 257.6% 0.2 0.1 188.7% 
Clostridia 247.1 10.7 20.4% 241.9 9.2 17.7% 
Mollicutes 4.5 0.3 36.1% 4.7 0.3 29.0% 
Bacilli 9.9 0.5 24.1% 11.9 0.5 20.1% 
Actinobacteria 10.2 0.9 41.8% 11.0 1.0 42.3% 
Spirochaetes 0.6 0.2 124.1% 0.8 0.2 104.2% 
Bacteroidetes 26.0 2.4 43.3% 26.5 1.9 34.1% 
Fusobacteria 0.1 0.1 323.7% 0.1 0.1 257.6% 
Verrucomicrobiae 0.7 0.1 62.7% 0.6 0.1 77.4% 
Lentisphaerae 0.3 0.1 149.8% 0.1 0.1 257.6% 
Total 306.0 13.6 20.9% 306.0 11.6 17.8% 
Table 3.2 presents the mean number of present probesets detected for kHLT and kIBS 
samples, standard error, and coefficients of variation. The mean total number of probesets 




Comparison of Intestinal Microbiota Abundance at Genus Level 
 While examining the composition of the intestinal microbiota at class level provides 
a broad picture of present organisms, examining the composition at lower phylogenetic 
levels, such as genus level, provides a more complete picture of the individual 
microorganisms that make up the intestinal microbiota across different sample groups, and 
may help identify key differences between groups. Although the Microbiota Array can detect 
phylo-species from 115 genera, many are either not detected or detected at very low levels. 
Genera present at 1.5% relative abundance or higher for at least one sample group are shown 
in Table 3.3. Twelve genera listed in Table 3.3 belong to the class Clostridia, which made up 
the majority of relative abundance at class level. Ruminococcus was by far the most abundant 
genus detected in both kHLT and kIBS samples, with mean abundances of 21.5% and 23.0%, 
respectively. Among all genera listed, Ruminococcus also had the lowest coefficient of 
variation. Faecalibacterium, the second most abundant genus, was present at 9.1% mean 
abundance in kHLT samples and 9.4% in kIBS samples. Bifidobacterium, a member of class 
Actinobacteria, was present at 8.4% relative abundance on average in kHLT samples and 
6.5% in kIBS samples. Mean relative abundance of Prevotella was 3.5 times higher in kIBS 
samples, however; this difference can mainly be attributed to two individual kIBS samples 
(kIBS04 and kIBS17) which had over 7% relative abundance of Prevotella. No significant 
differences were observed between sample groups (p<0.05).  
























































Clostridium Clostridia 2.8% 0.2% 2.6% 0.2% 
Acetivibrio Clostridia 2.1% 0.2% 1.7% 0.1% 
Anaerotruncus Clostridia 3.3% 0.3% 2.7% 0.2% 
Dorea Clostridia 2.1% 0.1% 2.5% 0.2% 
Faecalibacterium Clostridia 9.1% 0.6% 9.4% 0.6% 
Subdoligranulum Clostridia 2.8% 0.2% 2.7% 0.2% 
Lachnospira Clostridia 3.3% 0.3% 3.0% 0.2% 
Anaerostipes Clostridia 2.3% 0.1% 2.5% 0.1% 
Roseburia Clostridia 5.3% 0.4% 5.9% 0.4% 
Ruminococcus Clostridia 21.5% 0.9% 23.0% 0.9% 
Eubacterium Clostridia 4.1% 0.2% 4.3% 0.3% 
Papillibacter Clostridia 5.6% 0.4% 5.9% 0.3% 
Streptococcus Bacilli 2.8% 0.4% 3.2% 0.3% 
Collinsella Actinobacteria 1.4% 0.3% 1.8% 0.3% 
Bifidobacterium Actinobacteria 8.4% 0.8% 6.5% 1.0% 
Bacteroides Bacteroidetes 6.0% 0.4% 5.9% 0.6% 
Prevotella Bacteroidetes 0.4% 0.2% 1.4% 0.5% 
Table 3.3 shows the average relative abundance and standard error of 17 selected genera for 
kHLT and kIBS samples.  
 
 
 Figures 3.2 and 3.3 present scatter plots showing the differences in relative 
abundances of bacterial genera between kHLT and kIBS samples. kHLT mean relative 
abundance values are plotted on the x-axis, and kIBS mean relative abundance values are 
plotted on the y-axis. Error bars represent standard error of the mean (SEM). Figure 3.2 
shows that the majority of the data points cluster below 1% relative abundance, which 
represent the genera that were either not present or present at very low levels. Also, it was 
noted that the vast majority of data points clustered around the diagonal, indicating that mean 
relative abundances of most genera did not show much variation on average between healthy 
adolescent samples and IBS samples. Figure 3.3 shows the mean relative abundances of 
genera present at <2.0% in samples.  
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Figure 3.2 presents a scatter plot of the mean relative abundances of all genera for kHLT and 
kIBS samples. Ruminococcus, present at 21.5% abundance in kHLT samples and 23.0% 





Figure 3.3: Mean Abundance at Genus Level for kHLT and kIBS samples for Genera 
with <2% Relative Abundance 
 
 
Figure 3.3 presents a scatter plot of the mean relative abundances of genera with <2% 







Figure 3.4 shows variation among individual samples in relative abundance values of 
the most abundant genera. The upper maximum was set to 25% relative abundance (shown in 
red), and the minimum was set to zero (shown in dark blue) Ruminococcus, 
Faecalibacterium, Bifidobacterium, and Bacteroides were the most abundant genera among 
individual samples. Relative abundance of genus Ruminococcus ranged from 14.2% to 32.9% 
in kHLT samples and from 15.5% to 31.9% in kIBS samples. Faecalibacterium ranged from 
4.3% to 15.1% in kHLT samples and from 0.0% (kIBS02) to 13.8% in kIBS samples. A 
reduction in Faecalibacterium has been associated with IBD in some studies (Friswell, et al., 
2010, Sokol, et al., 2009); therefore, subject kIBS02 may have been incorrectly diagnosed 
with IBS rather than IBD.  Bifidobacterium also varied widely in relative abundance among 
individual samples, and while a somewhat higher mean abundance was seen in kHLT 
samples (8.4% vs 6.5%), kIBS samples had more instances in which Bifidobacterium was 
either not present or present at very low abundance. In summary, all genera varied widely in 
relative abundance among individuals for both kHLT and kIBS samples, and many genera 
were not present in every sample.  









Figure 3.4A shows variation of relative abundances of genera for kHLT samples and Figure 





Comparison of Intestinal Microbiota Detection at Genus Level 
 The mean numbers of detected probesets for selected genera are listed in Table 3.4 
for kHLT and kIBS samples. Slight differences in the mean number of probesets detected 
were observed between kHLT and kIBS samples. 
 


















































Clostridium Clostridia 12.0 0.5 12.1 0.6 
Acetivibrio Clostridia 8.7 1.0 7.0 0.8 
Anaerotruncus Clostridia 16.4 1.2 13.4 1.0 
Dorea Clostridia 10.4 0.4 9.8 0.6 
Faecalibacterium Clostridia 13.2 0.4 13.6 0.7 
Subdoligranulum Clostridia 7.5 0.4 8.0 0.4 
Lachnospira Clostridia 6.1 0.2 5.8 0.3 
Anaerostipes Clostridia 5.6 0.3 5.5 0.3 
Roseburia Clostridia 23.5 0.8 24.0 1.0 
Ruminococcus Clostridia 73.2 2.0 72.8 1.6 
Eubacterium Clostridia 10.6 0.6 10.3 0.5 
Papillibacter Clostridia 27.3 2.1 27.0 2.0 
Streptococcus Bacilli 5.7 0.3 6.8 0.2 
Collinsella Actinobacteria 0.9 0.2 1.1 0.2 
Bifidobacterium Actinobacteria 6.4 0.6 5.8 0.7 
Bacteroides Bacteroidetes 17.5 1.3 18.0 1.1 
Prevotella Bacteroidetes 1.0 0.3 2.2 0.6 
Table 3.4 presents mean number of present probesets detected for kHLT and kIBS samples 







 In addition to examining differences in the intestinal microbiota composition between 
healthy children and children with IBS, the “core” microbiota was also investigated. The core 
microbiota is essentially bacterial phylo-species that are detected among all samples within a 
population. This concept of a core microbiota is important because it can identify and 
separate “indisposable” phylo-species that are present in all samples from those that are 
detected in only a subset of samples. For example, a phylo-species detected in all 44 samples 
analyzed may be more likely to play a significant role in intestinal health and digestion than a 
phylo-species detected only sporadically. The number of phylo-species detected in two or 
more individual samples (shared phylo-species) and those detected only in one individual 
sample (unique phylo-species) were also determined for each sample group.  The shared 
species represent the “disposable” core, which also may have important roles in digestion and 
the breakdown of dietary nutrients, although they are not detected in all samples. Those 
species detected in only a single sample may not play a major role in the digestive process 
overall, but could possibly be related to the diet of the individual donor. It is also possible that 
the core microbiota is closely related to the general tolerance of the immune system of 
healthy humans towards particular commensal phylo-species of intestinal microbiota.  The 
immune systems of individual human subjects may vary with regards to tolerance of different 
bacterial species within the GI tract, which may also affect the numbers of shared phylo-
species. 
 Analysis of each sample group individually revealed that there were 56 core phylo-
species detected in kHLT samples and 46 core phylo-species detected in kIBS samples 
(Figure 3.5). Of these, 34 were detected in every sample for both groups, while 22 phylo-
species were detected consistently across all kHLT samples and 12 across all kIBS samples 
(Figure 3.6). Figure 3.5 also shows the numbers of phylo-species detected in at least two 
39 
 
individual kHLT or kIBS samples (shared), and the number of phylo-species present only in 
one sample for a group (unique). Figure 3.7 shows the genus composition of the 34 probesets 
called present in every sample across both groups.  Twenty-five probesets, or 73%, belonged 
to Ruminococcus, while three probesets belonged to Roseburia, and two to Streptococcus. 
One phylo-species from Clostridium, Lachnospira, Anaerostipes, and Papillibacter 
contributed the remaining probesets. Table 3.5 also shows the composition at genus level of 
the probesets detected across all samples and for each sample group individually. 
Ruminococcus contributed the greatest number of core probesets in all sample groups, while 
Faecalibacterium probesets only contributed to the core phylo-species of kHLT samples. 
This may be due to the lack of Faecalibacterium in sample kIBS02 (discussed previously).  
 
Figure 3.5: Core, shared, and unique phylo-species detected for each sample group or 
individual sample 
        
          kIBS            kHLT 
 
Figure 3.5 shows the number of phylo-species detected among all individual samples (core) 
for each sample group, the number of phylo-species shared by at least two individual samples 








Figure 3.6: Core phylo-species detected in kHLT and kIBS groups 
 
Figure 3.6 shows the number of phylo-species detected consistently across both sample 
groups and across each group individually. 
 
Note: Special thanks go to Richard Agans for creating the illustrations used in Figures 3.5 











































Ruminococcus 25 6 4 
Faecalibacterium - 5 - 
Roseburia 3 4 1 
Papillibacter 1 1 1 
Streptococcus 2 - 1 
Clostridium 1 3 1 
Lachnospira 1 - - 
Anaerostipes 1 - 1 
Turicibacter - 1 - 
Anaerotruncus - 1 - 
Dorea - 1 - 
Acetivibrio - - 1 
Bacteroides - - 1 
Subdoligranulum - - 1 
Total probesets 34 22 12 
Table 3.5 presents number of probesets detected for each genus across all samples (kHLT and 





Principal Components Analysis 
 Principle Components Analysis of experiments was carried out using Genesis. The 
two sample groups did not separate in PCA space. kHLT samples are shown in blue and kIBS 
samples in red (Figure 3.8).  
 
Figure 3.8: Principle Components Analysis  
 
Figure 3.8 shows results of Principle Components Analysis of experiments. 
 
 
qPCR Validation of Microbiota Array Results 
 
 Quantitative real-time PCR was carried out to validate results obtained by 
microarray. Reverse primers for Bifidobacterium, Papillibacter, Prevotella, and 
Faecalibacterium were either selected from literature or developed in our lab. These primers 
were tested first with qualitative PCR, and agarose gel electrophoresis was carried out to 
ensure that binding of the primers occurred only at the intended positions and that the 
amplicon sizes were correct. The 27F_v4 universal primer was used as the forward primer. 
One sample from each group (kIBS17 and kHLT12) was selected for qPCR analysis based on 
contrasting microarray results. qPCR reactions were carried out for 40 cycles. Melting curves 
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were also constructed to ensure that binding of primers only occurred in one position. The 
results showed that the ratios of relative abundance were in good concordance, although the 
ratio of Prevotella was higher for microarray results compared to qPCR results. This may be 
due to the highly sensitive and variable nature of qPCR reactions. 
 
Table 3.6: Results of qPCR Validation Experiments 
Genus Microarray Results qPCR results*
Bifidobacterium 0.3 0.1±0.1 
Papillibacter 0.6 0.4±0.1 
Prevotella 15.6 3.8±0.4 
Faecalibacterium 1.0 0.8±0.5 
Table 3.6 shows the ratio of relative abundance (kIBS to kHLT) obtained by microarray and 
by qPCR. Only the results from the 500pg starting gDNA reactions were used in calculation 
of qPCR results.  







This study aimed to examine differences in the intestinal microbiota between 
adolescents newly-diagnosed with IBS-D and healthy adolescents through the use of a 
custom Microbiota Array. Although there have been previous publications which investigated 
the differences in the intestinal microbiota between healthy adults and those with IBS, there 
has been a lack of studies involving adolescent patients. In addition, those studies did not 
quantitatively interrogate the entire intestinal microbiome; they only measured levels of 
certain selected phylo-species through qPCR and sequencing methods. In contrast, the 
utilization of a microarray in this study gave a much more comprehensive picture of the 
composition of the intestinal microbiota of healthy and IBS patients.  
Twenty-two fecal samples were collected from individuals in each group. Bacterial 
gDNA was extracted from each sample and 16S rDNA was amplified with PCR, which was 
fragmented, end-labeled with biotin, and hybridized to the Microbiota Array. On average, 
306 probesets were detected for each sample group. Much variation in relative abundance 
among individual samples was observed at both class and genus levels for healthy and IBS-D 
groups. No significant differences in mean relative abundance were seen at class or genus 
level, which differs from previous studies involving healthy and IBS adults (Kerckhoffs, et 
al., 2009, Lyra, et al., 2009, Matto, et al., 2005, Maukonen, et al., 2006, Kassinen, et al., 
2007, Krogius-Kurrika, et al., 2009, Tana, et al., 2010). Sample groups also failed to separate 
in PCA space. Overall, the results suggest that while a few consistencies with previous 
studies were seen at genus level, no statistically significant differences were observed 
between sample groups. Lower amounts of Bifidobacterium (6.5% vs 8.4%) and higher 
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amounts of Veillonella (0.5% vs 0.3%) and Lactobacillus (0.2% vs 0.0%) were observed in 
kIBS samples, which are consistent with the findings of Kerckhoffs, et al., 2009 and Tana, et 
al., 2010. 
 There are several possible explanations for these findings. Currently, the exact role of 
the intestinal microbiota in IBS is unknown. Some studies indicate that IBS may result from 
previous gastrointestinal infection (post-infectious IBS), while others suggest that host 
immune response may be an important factor in development of IBS (Quigley, 2011). Several 
studies have reported associations between levels of certain bacterial phylo-species and IBS 
(Lyra, Matto, Maukonen, Kassinen, Krogius-Kurrika, Tana), however; it cannot be said at 
this time whether or not these phylo-species have a role in the actual development or 
morbidity of IBS. It is also possible that shifts in the microbiota are seen as a result of the 
symptoms of the disease itself after a period of time. Also, while somewhat controversial, 
some studies have also suggested that SIBO (small intestinal bacterial overgrowth) may play 
a role in the symptoms of IBS (Rana, Scarpellini, Karantanos, Lin, Bouhnik). According to 
Lin, et al., 2004, in the healthy individual, easily digestible starches, such as rice, undergo 
complete digestion and absorption in the proximal small intestine, and are not available for 
fermentation in the distal gut. Fermentation of poorly digestible starches, such as beans, takes 
place in the distal gut. However, in SIBO, fermentation of poorly digestible starches takes 
place in the ileum, leading to gas production in the small intestine. With more fermentation 
occurring in the ileum and fewer nutrients reaching the distal gut, they theorize that the distal 
gut bacteria move proximally into the small intestine. If the symptoms of IBS are related to 
bacterial overgrowth in the small intestine, it may be unlikely that differences would be 
detected in the fecal microbiota between IBS subjects and healthy subjects. In addition, while 
a jejunal aspiration and culturing study by Bouhnik, et al., 1999 reported the presence of 
Veillonella and Lactobacillus in SIBO patients, many of the genera detected are also found in 
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the fecal samples of healthy subjects. In regards to the wide sample-to-sample variation 
observed, diet could be an influencing factor. There were no dietary guidelines or restrictions 
for the sample donors, except that they were not to have been taking antibiotics within the 
previous three months or consuming probiotic supplements. Certain bacterial species, such as 
Ruminococcus flavefaciens, are responsible for the enzymatic breakdown of plant cell wall 
polysaccharides, while Bacteroides thetaiotamicron is a known starch degrader (Louis). Also, 
fructo- and galacto-oligosaccharides have been shown to selectively stimulate the growth of 
Bifidobacterium and Lactobacillus species (Louis). Different diets could lead to variations in 
the types and amounts of dietary compounds available for microbial breakdown, so it is 
plausible that growth of some groups of bacteria may be stimulated or inhibited depending on 
their particular nutrient requirements and ability to break down certain dietary compounds.  
In addition to the primary breakdown of nutrients, other studies have also shown that 
there is metabolic “cross-feeding” between different groups of bacteria. This cross-feeding 
could also play an important role in the composition of the intestinal microbiota as it relates 
to diet. A recent review by De Vuyst and Leroy discusses the breakdown of inulin-type 
fructans (found naturally in bananas, onions, garlic, leeks, and chicory) by the Bifidobacteria, 
which results in increased production of lactate, acetate, and butyrate. While Bifidobacteria 
can produce lactate and acetate, they do not possess a pathway for butyrate production in 
their genomes. However, several other studies have shown that other members of the gut 
microbiota can utilize acetate and lactate to produce butyrate. Belenguer, et al., showed that 
lactate-utilizing bacteria Eubacterium hallii and Anaerostipes caccae produce butyrate when 
grown in a co-culture with Bifidobacterium adolescentis. They also proposed that Roseburia 
spp., while not able to utilize lactate, can consume oligosaccharides produced by B. 
adolescentis to synthesize butyrate. Another recent study by Chalmers, et al., found that 
Streptococcus and Veillonella spp. co-aggregate in dental plaques. Veillonella spp. are non-
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saccharolytic; therefore, they are metabolically dependent on other species to provide SCFAs. 
In this case, lactic acid produced by Streptococcus is utilized as a carbon source by 
Veillonella. While this co-aggregation has not been directly observed in fecal samples, it is 
plausible that intestinal species could have a similar metabolic relationship. Unfortunately, 
there is insufficient information available about the roles of many of the members of the 
distal gut microbiota at lower phylogenetic levels in the breakdown of nutrients, which could 
be an interesting area for future work. Greater understanding of the metabolic capabilities of 
the intestinal microbiota at low phylogenetic levels and the metabolic relationships between 
them, combined with analysis of the diets of the fecal sample donors may shed light on the 
variations in the microbiota composition between individuals.  
The microbiota core was also determined for both sample groups and for each sample 
group individually. Thirty-four bacterial phylo-species were detected consistently across all 
fecal samples. Twenty-two phylo-species were detected across all healthy adolescent 
samples, and twelve were detected across all IBS adolescent samples. The “shared” 
microbiota core, or phylo-species detected among two or more samples for a group, and the 
phylo-species detected in only one sample for a group (unique) were also determined. 
Analysis of the core microbiota may help to show which species are necessary and 
“indisposable” in the distal gut.  A phylo-species found to be present across all samples may 
play a more important role in the digestive process than a species present in only a subset of 
samples. Ruminococcus species comprised 73% of the core microbiota across all samples. As 
primary plant cell wall degraders, Ruminococcus species not only made up the majority of the 
core microbiota, but also composed the most abundant genus overall at approximately 22% 
relative abundance. It also may be important to note that many of the core microbiota genera 
were also represented by at least two percent relative abundance.  
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Overall, we were able to examine the composition of distal gut microbiota of healthy 
adolescents and adolescents suffering from IBS-D and gain a better understanding of the 
relationship of the microbiota to disease. In contrast to the findings of several adult studies, 
no significant differences were found in microbiota composition at class or genus level 
between healthy and IBS fecal samples, but a few consistencies with previous studies were 
observed. Future efforts may focus on deeper understanding of the nutritional requirements 
and capabilities of lesser known intestinal bacterial genera such as Papillibacter, Roseburia, 
Dorea, Anaerotruncus, Lachnospira, and Eubacterium. These genera, while not nearly as 
abundant as Ruminococcus and Faecalibacterium, are generally present in most (if not all) 
samples, and usually represent at least two percent of the relative abundance. Understanding 
the metabolic capabilities of individual genera may also aid in determining the metabolic 
relationship of one genus to another. While this study focused on newly-diagnosed IBS-D 
patients, it might also be interesting to focus on the changes in microbiota of IBS and healthy 
patients over time by collecting fecal samples from the same patients at regular intervals. This 
may also help to answer the question of whether IBS is actually caused by some form of 
dysbiosis, or if the reported differences between IBS and healthy may be a result of the 
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